Details of Disease

General Information of Disease (ID: DIS18PD0)

• Disease Name: Idiopathic parkinson disease
• Synonyms: secondary Parkinsonism; disorder presenting primarily with parkinsonism; symptomatic parkinsonism; secondary parkinsonism, unspecified; secondary parkinsonism (disorder) [ambiguous]
• Disease Class: 8A00: Parkinsonism
• Definition: A condition with a clinical picture similar to that of Parkinson disease, but which is caused by external factors, including medication.
• Disease Hierarchy:
  DISM20FF: Neurodegenerative disease
  DIS18PD0: Idiopathic parkinson disease
• ICD Code:
  ICD-11: ICD-11: 8A00.0Z
  ICD-9: ICD-9: 332
  Expand ICD-11: '8A00.0Z
  Expand ICD-9: 332
• Disease Identifiers:
  MONDO ID: MONDO_0006966
  MESH ID: D010302
  UMLS CUI: C0030569
  MedGen ID: 10592
  SNOMED CT ID: 230292008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Apomorphine	DMX38HQ	Approved	Small molecular drug	[1]
Safinamide	DM0YWJC	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB1	TT3OT40	moderate	Biomarker	[3]
BCHE	TT3MSAO	moderate	Biomarker	[4]
CNR2	TTMSFAW	moderate	Biomarker	[5]
GDNF	TTF23ML	moderate	Therapeutic	[6]
PON1	TT9LX82	moderate	Biomarker	[3]
RGS2	TTKB7T3	moderate	Biomarker	[7]
SHH	TTIENCJ	moderate	Therapeutic	[8]

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ATP13A2	OTKWBUGK	moderate	Biomarker	[9]
FMC1	OTO2EE3K	moderate	Biomarker	[10]
PRKN	OTJBN41W	moderate	Biomarker	[11]
TFAM	OTXXV5V7	moderate	Biomarker	[12]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8291).
• [3] Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease.Environ Res. 2015 Nov;143(Pt A):98-106. doi: 10.1016/j.envres.2015.08.022. Epub 2015 Oct 19.
• [4] K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt.Sci Rep. 2018 Nov 8;8(1):16525. doi: 10.1038/s41598-018-35003-4.
• [5] Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.Exp Neurol. 2016 Sep;283(Pt A):204-12. doi: 10.1016/j.expneurol.2016.06.014. Epub 2016 Jun 15.
• [6] Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.J Neurol Sci. 2010 Mar 15;290(1-2):123-30. doi: 10.1016/j.jns.2009.09.032. Epub 2009 Nov 11.
• [7] Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region.Pharmacogenomics J. 2009 Apr;9(2):103-10. doi: 10.1038/tpj.2008.6. Epub 2008 Mar 18.
• [8] Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease.Exp Neurol. 2002 Jan;173(1):95-104. doi: 10.1006/exnr.2001.7825.
• [9] ATP13A2 (PARK9) polymorphisms influence the neurotoxic effects of manganese.Neurotoxicology. 2012 Aug;33(4):697-702. doi: 10.1016/j.neuro.2012.01.007. Epub 2012 Jan 20.
• [10] Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism.EMBO Rep. 2018 Mar;19(3):e44860. doi: 10.15252/embr.201744860. Epub 2018 Jan 25.
• [11] Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice.Neuropharmacology. 2005 Aug;49(2):208-19. doi: 10.1016/j.neuropharm.2005.03.003.
• [12] Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.Neurotoxicology. 2018 Jan;64:240-255. doi: 10.1016/j.neuro.2017.06.002. Epub 2017 Jun 20.